In This Section      
 

Search Results

Title:
E1910 A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults
Protocol Number:
NCTNE1910
Phase:
Phase III
Physician:
Keith Pratz
Sites:
Johns Hopkins Kimmel Cancer Center in Baltimore
Purpose:
This research is being done to determine what affects (good and bad) the therapy blinatumomab has on your type of cancer (BCR/ABL negative ALL). This new therapy will be added to what has traditionally been used to treat your specific sub-type of ALL. Studies are being done in ALL and other blood cancers with blinotumomab. It is hoped that blinatumomab will target your B-cell ALL and destroy these specific cells, but it has not yet been proven.
Eligibility:
People between the ages of 35 and 70 years and have been recently diagnosed with a subtype of acute lymphoblastic leukemia (ALL) that is known as BCR-ABL negative B-lineage ALL may join.
Treatment:
There are several steps of treatment in this study. They are called induction, intensification, consolidation, and maintenance. In these study steps you will be getting standard chemotherapy treatments that may or may not be combined with a new cancer drug called blinatumomab. Your doctor may recommend you to have a blood or marrow transplant (BMT) at a later date after randomization to the blinatumomab/no blinatumomab arms, if you have a suitable donor.
Population:
Adult
Last Update
03/05/2019 05:03 AM